IL13RA2 and osteosarcoma: Considering the therapeutic implication of overcoming resistance to anticancer cytotoxic agents of osteosarcomas, the impact of IL-13Rα2 knockdown or overexpression on cell proliferation and apoptosis in response to doxorubicin treatment was evaluated.